Research and Innovation in Personalized Medicine: a Descriptive Synthesis of Actors in the EU and China

Abstract

Aim: Research and innovation (R&I) actors are fundamental in shortening the translational gap of personalized medicine in health systems. In the context of the ‘Integrating China in the International Consortium for Personalized Medicine’ project, we aimed to map the current landscape of R&I actors in the field of personalized medicine in the EU and China. Methods: A two-phase desk research study was conducted. Results: We identified 78 R&I actors. Research and technology organizations were the most frequent in both the EU and China. The identified R&I actors were active in a wide range of fields. The EU and China have many different R&I actors addressing personalized medicine-related issues, with few characteristics in common. Conclusion: More efforts are needed to ensure these R&I actors are encouraged to work together to bridge each other’s gaps.

A Roadmap for Personalized Medicine: the findings of the IC2PerMed Project

“…Concerning industry and universities, which are the main actors in PM research and innovation in the EU and China [17], the results refer to the importance of investments of translating research into the market and partnerships between industrial partners and academia. Collaborations hold large economic potential, where global leaders can extend their reach and value chains to new markets.…”

“…Findings were revised and expanded through a survey of 47 experts, from EU and China, exploring the main areas of interest and the international collaborations in place [10]. The results were disseminated in scienti c papers and publicly available deliverables [9,[14][15][16][17].…”